Utilizing KIBIT, we extract a large number of unreported target genes and further narrow them down to more reliable targets using our unique analysis method.
KIBIT generates a network that maps the connections between genes related to diseases. In doing so, it also predicts target genes that are not mentioned in the literature regarding their association with the disease. To extract high-probability targets from these target genes, it utilizes an innovative analysis method called "Drug Discovery Best Known Method (DD-BKM)" to narrow down to targets with a high potential for new drug development.
Inquire About This Product
basic information
Utilizing our in-house developed AI "KIBIT," we discovered unreported target genes with a high relevance to diseases. We extracted target genes with a high probability of success using our unique analysis method. We created a gene network and generated hypotheses for the unreported target genes.
Price range
Delivery Time
Applications/Examples of results
The target papers for analysis are primarily from PubMed, with the option to include papers from Springer Nature. FRONTEO's drug discovery support service is characterized by its ability to extract highly novel target genes from already reported paper information. Analysis incorporating genomic information and OMICS data is also possible.
Detailed information
-
We virtually knock out (KO) the genes of interest and simulate how the pathways change. For example, in the figure below, knocking out gene B has almost no impact on the network as it is simply replaced by gene D, whereas knocking out gene C results in significant changes to the network, suggesting that gene C is a gene that affects the disease.
News about this product（1）
Company information
FRONTEO supports the judgments of experts in various fields who confront social issues day and night through the provision of its proprietary specialized AI, "KIBIT." This creates a starting point for innovation. Our unique natural language processing technology (patented in Japan and the U.S.) enables fast and high-precision analysis without relying on the amount of training data or computing power, unlike general-purpose AI. Additionally, by utilizing our patented technology that maps (visualizes the structure of) the analyzed information, "KIBIT" can directly influence the insights of experts. In recent years, KIBIT's technology has also been applied to hypothesis generation and target exploration in drug discovery. Through KIBIT's unique technology and approach, we are promoting social implementation in the fields of life sciences AI, business intelligence, economic security, and legal tech AI, with the aim of realizing our philosophy of "providing solutions that do not overlook risks and opportunities buried in records, and achieving fairness in the information society."
![[Technical Document] Current Status of CAE Prediction Technology for Processing Limits in Bulk Molding](https://image.mono.ipros.com/public/product/image/22f/2001021331/IPROS35700120040990786932.png?w=280&h=280)
